TG Therapeutics (NASDAQ:TGTX) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

TG Therapeutics (NASDAQ:TGTX) released its quarterly earnings results on Monday. The biopharmaceutical company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.02), FiscalAI reports. TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The company had revenue of $259.94 million during the quarter, compared to analyst estimates of $245.47 million. During the same quarter last year, the company earned $2.43 EPS. The firm’s quarterly revenue was up 60.8% compared to the same quarter last year.

Here are the key takeaways from TG Therapeutics’ conference call:

• Positive sentiment: TG raised 2026 guidance to approximately $1 billion in global revenue, including $915 million–$920 million in U.S. BRIUMVI sales. Q3 revenue was about $260 million, up 61% year over year, and the company reported $86 million in operating income.
• Positive sentiment: BRIUMVI continued to gain commercial traction, with U.S. sales up 52% year over year and 14 consecutive quarters of sequential growth. Management cited accelerating new-patient starts, record prescriber activity, stronger hospital sales, and high persistence, while noting that it has not provided 2027 guidance.
• Positive sentiment: TG is advancing two potential BRIUMVI enhancements: a simplified single-dose IV initiation regimen, with a possible mid-2027 label update, and quarterly self-administered subcutaneous BRIUMVI, with Phase III results expected around year-end or early 2027 and a potential 2028 launch. These timelines depend on trial results and regulatory review.
• Neutral sentiment: Early azer-cel results in 26 progressive MS patients showed no dose-limiting toxicities and stable or improved disability scores in nearly 90% of evaluable patients at day 90. The findings are preliminary, and TG said longer-term follow-up is ongoing.

TG Therapeutics Stock Up 5.9%

Shares of TGTX stock opened at $63.38 on Tuesday. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. TG Therapeutics has a 1 year low of $26.76 and a 1 year high of $63.60. The firm’s fifty day moving average price is $55.99 and its two-hundred day moving average price is $44.66. The firm has a market capitalization of $9.70 billion, a P/E ratio of 23.13, a PEG ratio of 2.60 and a beta of 1.89.

Key TG Therapeutics News

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Third-quarter revenue was $259.9 million, up 60.8% year over year and above the roughly $245.5 million analyst estimate, reflecting BRIUMVI’s momentum. TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance
• Positive Sentiment: TG Therapeutics raised its 2026 revenue guidance to $1.0 billion, above the approximately $961 million consensus estimate. CEO Michael Weiss also said global revenue could exceed $1 billion, reinforcing expectations for continued growth. TG Therapeutics targets $1B 2026 global revenue and outlines dosing plans
• Positive Sentiment: The company plans simplified IV dosing for BRIUMVI around mid-2027 and a subcutaneous launch in 2028. These potential administration improvements could support future adoption, though they remain forward-looking plans. TG Therapeutics targets $1B 2026 global revenue and outlines dosing plans
• Negative Sentiment: Reported EPS of $0.35 fell short of the $0.37 consensus estimate cited by some analysts, tempering the otherwise strong revenue result. Estimates varied across sources, with one Zacks report showing a lower $0.28 benchmark. TG Therapeutics Q3 earnings report

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TGTX. Weiss Ratings upgraded shares of TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, November 4th. Zacks Research raised shares of TG Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 4th. HC Wainwright reaffirmed a “buy” rating and issued a $78.00 target price on shares of TG Therapeutics in a research note on Tuesday, September 1st. JPMorgan Chase & Co. increased their target price on TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, B. Riley Financial lifted their price target on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research note on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, TG Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $63.00.

Insider Buying and Selling

In other news, Director Laurence Charney sold 5,000 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $54.96, for a total transaction of $274,800.00. Following the completion of the transaction, the director directly owned 168,640 shares in the company, valued at $9,268,454.40. This represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 8.87% of the stock is owned by company insiders.

TG Therapeutics Company Profile

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions.

The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

Headquartered in New York, TG Therapeutics serves patients in the United States and has expanded BRIUMVI’s availability into international markets, including Europe.